Nicoletti, Eileen
Rao, Gayatri
Bueren, Juan A.
Río, Paula
Navarro, Susana
Surrallés, Jordi
Choi, Grace
Schwartz, Jonathan D.
Article History
Received: 25 July 2019
Accepted: 6 February 2020
First Online: 17 February 2020
Compliance with ethical standards
:
: Eileen Nicoletti is an employee of Rocket Pharmaceuticals, Inc. Gayatri Rao is an employee of Rocket Pharmaceuticals, Inc. Juan A. Bueren is the head of the Hematopoietic Innovative Therapies Division at Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT) which receives funding for Fanconi Anemia (FA) gene therapy and has licensed the PGK-FANCA-Wpre* lentiviral vector to Rocket Pharmaceuticals, Inc. He is also a consultant for Rocket Pharmaceuticals, Inc. Paula Río is a member of the Hematopoietic Innovative Therapies Division at Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT) which receives funding for Fanconi Anemia (FA) gene therapy and has licensed the PGK-FANCA-Wpre* lentiviral vector to Rocket Pharmaceuticals, Inc. Susana Navarro is a member of the Hematopoietic Innovative Therapies Division at Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT) which receives funding for Fanconi Anemia (FA) gene therapy and has licensed the PGK-FANCA-Wpre* lentiviral vector to Rocket Pharmaceuticals, Inc. Jordi Surrallés does not have any conflicts of interest. Grace Choi is an employee of Rocket Pharmaceuticals, Inc. Jonathan D. Schwartz is an employee of Rocket Pharmaceuticals, Inc.
: This article does not contain any studies with human participants or animals performed by any of the authors.